FSRH Clinical Effectiveness Unit comment on the use of Sodium Valproate and its pregnancy risks - 2016

Posted 8 February 2016

Date: 08 Feb 2016

Type: FSRH Clinical Guidance and Clinical Statements

FSRH’s Clinical Effectiveness Unit comments on Sodium Valproate and the risks it carries if used during pregnancy.

This statement follows the Medical and Healthcare products Regulatory Agency (MHRA) launch of a toolkit for healthcare professionals to highlight Sodium Valproate’s teratogenic effects.